I am in agreement the stock will not fly with a UK launch. The price will stabalize. We will start to see traction when we have several countries quickly implementing a launch. It is not the V sales that will drive the price. It is the validation that the undeerlying delivery system works (nexact) and that's when we will be bought out. Holding out for Femprox would not be in our best intesrest. It will be almost 3 years to recruit, analyze and complete two trials along with the regulatory delay for approval. In the US, you are then open to the whim of the FDA and what agenda they happen to be driving at that time. The drug could also fail the efficacy hurdle.
The value is the product pipeline that can be developed using Nexact. Existing drugs brought to market through a new delivery system would go through the faster 505b approval process (US only). The best suitor for shareholders is Actavis because of the drugs they inherited from Warner Chilcott (dermatology line of products) Imagine replacing injectables with a Nexact base. That is the value!
News 
Market Data 
Discover 
AI
